Education
About Us
Working with TipRanks
Follow Us
Laboratorios Farmaceuticos Rovi, SA (GB:0ILL)
LSE:0ILL
RESEARCH TOOLSreports
Total Valuation
Laboratorios Farmaceuticos Rovi has a market cap or net worth of €2.74B. The enterprise value is €2.89B.
Market Cap€2.74B
Enterprise Value€2.89B
Share Statistics
Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,235,764
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 19.73%.
Return on Equity (ROE)0.24
Return on Assets (ROA)0.16
Return on Invested Capital (ROIC)19.73%
Return on Capital Employed (ROCE)0.27
Revenue Per Employee347.63K
Profits Per Employee80.88K
Employee Count2,197
Asset Turnover0.92
Inventory Turnover0.86
Valuation Ratios
The current PE Ratio of Laboratorios Farmaceuticos Rovi is 20.8. Laboratorios Farmaceuticos Rovi’s PEG ratio is -1.25.
PE Ratio20.8
PS Ratio4.23
PB Ratio5.64
Price to Fair Value5.64
Price to FCF42.43
Price to Operating Cash Flow19.87
PEG Ratio-1.25
Income Statement
In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 763.75M and earned 136.88M in profits. Earnings per share was 2.67.
Revenue763.75M
Gross Profit478.35M
Operating Income179.54M
Pretax Income177.69M
Net Income136.88M
EBITDA207.69M
Earnings Per Share (EPS)2.67
Cash Flow
In the last 12 months, operating cash flow was 136.55M and capital expenditures -64.39M, giving a free cash flow of 72.17M billion.
Operating Cash Flow136.55M
Free Cash Flow72.17M
Free Cash Flow per Share1.41
Dividends & Yields
Laboratorios Farmaceuticos Rovi pays an annual dividend of €0.757, resulting in a dividend yield of 1.4%
Dividend Per Share€0.757
Dividend Yield1.4%
Payout Ratio65.15%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.71
52-Week Price Change-24.25%
50-Day Moving Average54.40
200-Day Moving Average56.66
Relative Strength Index (RSI)49.74
Average Volume (3m)13.81K
Important Dates
Laboratorios Farmaceuticos Rovi upcoming earnings date is Nov 6, 2025, TBA (Confirmed).
Last Earnings DateJul 24, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend DateJul 14, 2025
Financial Position
Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 22.94%
Current Ratio3.14
Quick Ratio1.03
Debt to Market Cap0.03
Net Debt to EBITDA0.42
Interest Coverage Ratio76.40
Taxes
In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 40.81M in taxes.
Income Tax40.81M
Effective Tax Rate0.23
Enterprise Valuation
Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 15.96, with an EV/FCF ratio of 43.58.
EV to Sales4.34
EV to EBITDA15.96
EV to Free Cash Flow43.58
EV to Operating Cash Flow23.97
Balance Sheet
Laboratorios Farmaceuticos Rovi has €47.62M in cash and marketable securities with €129.30M in debt, giving a net cash position of €81.68M billion.
Cash & Marketable Securities€47.62M
Total Debt€129.30M
Net Cash€81.68M
Net Cash Per Share€1.59
Tangible Book Value Per Share€10.68
Margins
Gross margin is 85.63%, with operating margin of 23.51%, and net profit margin of 17.92%.
Gross Margin85.63%
Operating Margin23.51%
Pretax Margin23.27%
Net Profit Margin17.92%
EBITDA Margin27.19%
EBIT Margin23.53%
Analyst Forecast
The average price target for Laboratorios Farmaceuticos Rovi is €75.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€75.00
Price Target Upside38.76% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―